PTC Therapeutics, Inc. Effect of Exchange Rate on Cash, Continuing Operations
PTC Therapeutics, Inc. (PTCT) reported Effect of Exchange Rate on Cash, Continuing Operations of -$394.00 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashContinuingOperations · last filed 2017-05-08
- PTC Therapeutics, Inc. effect of exchange rate on cash, continuing operations for the quarter ending 2017-03-31 was -$394.00K, a 124.95% decline year-over-year.
- PTC Therapeutics, Inc. effect of exchange rate on cash, continuing operations for the quarter ending 2016-03-31 was $1.58M.
- PTC Therapeutics, Inc. effect of exchange rate on cash, continuing operations for the quarter ending 2015-03-31 was -$124.00K.
- PTC Therapeutics, Inc. effect of exchange rate on cash, continuing operations for fiscal 2015 was -$639.00K.
- PTC Therapeutics, Inc. effect of exchange rate on cash, continuing operations for fiscal 2014 was -$350.00K.
| Period end | Effect of Exchange Rate on Cash, Continuing Operations 3 month | Effect of Exchange Rate on Cash, Continuing Operations 6 month | Effect of Exchange Rate on Cash, Continuing Operations 9 month | Effect of Exchange Rate on Cash, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | -$394.00K 10-Q · filed 2017-05-08 | |||
| 2016-09-30 | $235.00K 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $660.00K 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $1.58M 10-Q · filed 2017-05-08 | |||
| 2015-12-31 | -$639.00K 10-K · filed 2016-02-29 | |||
| 2015-09-30 | -$89.00K 10-Q · filed 2016-11-03 | |||
| 2015-06-30 | $341.00K 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$124.00K 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | -$350.00K 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |